QbD FAQs: Practical Answers for CMC Development

Sofia Santos

Author

Sofia Santos

Product Strategist

ValGenesis

LinkedIn

Published on May 21, 2026
Reading time: -- minutes
Last updated on May 21, 2026
Reviewed by: Lisa Weeks

Summary

Quality by Design, or QbD, helps CMC teams define product goals, link critical quality attributes to process parameters, and set controls based on process understanding.

These FAQs cover QTPP, CQAs, CPPs, design space, DoE and control strategy. They also explain why spreadsheet-based QbD can limit traceability, complicate tech transfer and slow lifecycle decisions, and outline what to look for in a digital QbD environment.

Key Takeaways

  • QbD links QTPP to CQAs and CPPs, then uses that understanding to define the design space and build a control strategy, so quality is managed through process understanding rather than end-product testing alone.

  • Spreadsheet-based QbD creates version sprawl, weak auditability, and lost rationale, forcing teams to redo risk work during scale-up, transfer, and post-approval change.

  • Digital QbD supports a single source of truth, traceable change history, connected workflows, and knowledge reuse across the lifecycle.

Who is this for

  • CMC formulation scientists (drug product development)
  • Process development scientists and engineers (upstream/downstream or chemical process)
  • Analytical development scientists (method development/validation support for CQAs)
  • Tech transfer leads and MSAT (manufacturing science and technology)
  • Quality assurance professionals supporting development and PPQ
  • CMC regulatory affairs professionals preparing submissions and responses
  • Program/project managers leading CMC plans and cross-functional execution
featured image

Quality by Design (QbD) gives CMC teams a structured way to define product goals, identify the attributes and parameters that matter most, and build controls around them across development and manufacturing. But as teams apply QbD in practice, questions often arise around implementation, scalability, and how to manage knowledge across the lifecycle.

This post brings together clear, practical answers to the most common questions, covering core QbD concepts, the limitations of spreadsheet-based approaches, and the role of digital systems in traceability, tech transfer, lifecycle management, and future change decisions.

 

QbD Fundamentals: Concepts, Benefits, and Core Principles

What is Quality by Design (QbD)?
QbD is a systematic approach to development that starts with predefined objectives and emphasizes product and process understanding, process control, sound science, and quality risk management.

Why is QbD important for CMC development?
QbD is the framework that helps teams build quality into development instead of relying on end-product testing alone. It is used to strengthen quality, consistency, regulatory readiness, and decision-making across the lifecycle.

What are the main building blocks of a QbD framework?
The recurring building blocks are QTPP, CQAs, risk assessments, design space work, DoE where needed, control strategy, and lifecycle management.

How does QbD improve product quality and consistency?
QbD improves product quality by understanding variability, linking process inputs to quality attributes, and building controls around what really matters. The goal is a process that consistently meets predefined quality criteria.

How does QbD help with regulatory submissions?
QbD strengthens submissions because it shows a deeper understanding of product and process risks, design space, and controls. That can reduce agency questions and smooth the path to approval.

How does QbD help reduce cost and rework?
QbD is tied to fewer failed experiments, less end-product testing, less rework, and better use of development time. A stronger process understanding also reduces the need to rediscover past decisions later.

How does QbD support patient safety?
QbD protects patients by identifying which attributes and process parameters matter most and by building controls that keep those risks in check throughout development and manufacturing.

Why is QbD not just a set of files?
QbD is meant to be an evolving system of scientific understanding. Spreadsheets freeze knowledge at a point in time, which makes it harder to carry that understanding through tech transfer, validation, and commercial operations.

What happens when decision rationale is not preserved in QbD work?
Teams end up reconstructing decisions after the fact, especially when people change roles or projects move. That leads to rework, delay, and inconsistent decisions

 

Executing QbD: From QTPP to Design Space and Control Strategy

What are the basic QbD steps?
The sequence starts with QTPP, then identifies CQAs, evaluates risks, uses experiments to close knowledge gaps, defines design space, and establishes a control strategy that supports lifecycle management.

What is QTPP, and why does it matter?
QTPP sets the intended use and quality objectives for the product. It is the starting point for identifying CQAs and for keeping development work tied to patient and market needs.

How are CQAs identified in the case examples?
CQAs were identified through criticality assessments using product information, reference product data, process mapping, and risk-to-patient thinking. One case also classified attributes by impact and uncertainty.

How are CPPs determined?
CPPs are determined by linking process parameters to CQAs through tools such as a cause-effect matrix and then using risk assessment to determine which parameters are critical.

What is design space in QbD?
Design space is the multidimensional relationship between input variables or process parameters and product quality, within which quality is assured.

When should DoE be used in QbD work?
DoE is used when risk assessments reveal knowledge gaps and when teams need a data-driven basis to define or refine design space and understand factor interactions.

What makes a control strategy robust?
Robust control strategies are tied to a clear link between risks, critical attributes, critical parameters, normal operating ranges or design space, and the controls used in routine manufacturing.

How does QbD support scale-up and commercial development?
Small-scale design space and early knowledge need to be adapted at commercial scale because equipment and strategy changes can affect quality. Process risk assessment then helps define the commercial control strategy.

How does QbD help with future changes after development?
A maintained knowledge base makes it easier to assess the impact of changes such as supplier changes, equipment changes, or process improvement proposals from both a knowledge and risk perspective.

Why is QbD paired with process understanding instead of end-product testing alone?
Quality should be built into the product and process from the start. QbD focuses on understanding how inputs, parameters, and risks interact so quality can be controlled proactively.

How does QbD apply to cell and gene therapies?
Cell and gene therapies have more complex and patient-specific quality attributes, so they need a structured risk-based approach and a robust control strategy across the lifecycle to protect efficacy and patient safety.

How can QbD shorten time to market?
QbD helps teams define the right quality targets, focus experiments, formalize risk decisions, and build control strategies earlier. That reduces delays and supports smoother submissions and launch readiness.

How does QbD help create a stronger basis for continuous improvement?
QbD creates a living knowledge base and links it to lifecycle monitoring. That makes it easier to update risk assessments, refine controls, and improve the process without starting from zero each time.

 

Scaling QbD: Digitalization, Collaboration, and Lifecycle Management

How does version sprawl hurt QbD execution?
Different teams often end up with different versions of the same QbD work. When parameter ranges, risk rankings, and control assumptions drift apart, teams spend time reconciling documents instead of improving process understanding.

Why are spreadsheets a weak foundation for QbD traceability?
Spreadsheets make it hard to track authorship, change history, and the context of updates, especially when files are copied or edited outside controlled systems. That creates fragile data integrity and auditability.

Why is spreadsheet-driven QbD hard to scale across the lifecycle?
Spreadsheets capture point-in-time assessments rather than evolving understanding. As a result, teams often redo risk assessments and justifications during scale-up, site transfer, or post-approval change instead of reusing existing knowledge.

Why can a spreadsheet become a system risk in QbD work?
Spreadsheets often stop being simple documents and start acting like systems when they drive GMP-relevant decisions. If they are not governed like systems, the risk and the controls no longer match.

What is the biggest long-term cost of manual or spreadsheet-based QbD?
The biggest cost of manual- or spreedsheet-based QbD is slower organizational learning. Teams struggle to trend data, spot recurring risks, and apply learning across products and sites, so experience does not compound the way it should.

What daily delays does manual QbD create?
Manual QbD can create delays through disconnected systems, version confusion, and waiting for inputs from overloaded subject matter experts. Those bottlenecks add time at every stage of CMC development.

What types of errors does manual QbD create?
Manual QbD can create copy-paste mistakes, unclear rationales, and lost context when changes are made in silos. Those errors make quality decisions harder to explain and trust.

What frustrations does manual QbD create for scientists, QA, and leaders?
Scientists and engineers lose time formatting templates, QA and regulatory teams chase missing justifications, and leaders lose real-time visibility into risks and bottlenecks.

How does digital QbD help compared with manual QbD?
Digital QbD reduces repetitive data handling, connects workflows, improves traceability, supports shared visibility, and makes it easier to reuse knowledge instead of re-entering and reconciling data.

What capabilities should a digital QbD environment have?
A digital QbD environment should provide a single source of truth, traceable change history, lifecycle knowledge reuse, risk-based governance, and real-time collaboration across teams and sites.

What features should I look for in a QbD platform?
Look for a user-friendly interface, configurable risk management methods, regulatory-ready documentation, scalability and security, and support for advanced analytics or PAT integration where needed.

How does digital QbD support tech transfer?
Digital QbD gives sending and receiving teams a shared knowledge base, better traceability of rationale, less retyping, smoother PPQ, and fewer surprises when the process moves to a new site or partner.

Why is digital QbD a foundation for high-confidence tech transfer?
Because it keeps process knowledge structured, connected, and current from development onward. That gives receiving teams clearer rationale for decisions and reduces the need to reinterpret or rebuild the development story during transfer.

Can QbD support legacy products as well as new development?
Yes. Retrospective QbD shows that legacy products can be brought into a formal QbD framework by analyzing historical data, defining QTPP, CQAs, and CPPs, and rebuilding the control strategy on a science- and risk-based basis.

How does digital transformation strengthen QbD execution?
Digital tools reduce silos, improve information accessibility, automate routine work, support real-time reporting, and make QbD work easier to carry across product and analytical development.

What role does collaboration play in QbD?
QbD depends on multidisciplinary input from scientists, engineers, quality, manufacturing, and regulatory teams. Digital environments improve collaboration because everyone can work from the same current information.

How does a centralized repository help QbD teams?
A single repository keeps relevant information in one place, reduces fragmentation, makes historical work easier to find, and lowers the chance that teams make decisions from incomplete data.

How does automated reporting help QbD programs?
Automated reporting speeds up CQA assessment reports, control strategy summaries, and other documents needed for CMC submissions. That cuts manual effort and helps teams meet timelines.

QbD becomes much more manageable when its core concepts are broken down into practical questions and answers. In upcoming posts in this FAQ blog series, we'll continue exploring key topics in CMC development and process lifecycle management to help teams apply these practices with greater clarity and confidence.

 

 

 

 

 

Citations

1

European Medicines Agency. (n.d.). https://www.ema.europa.eu/en/human-regulatory-overview/research-development/quality-design

Quality by design (QbD). Accessed Date: 22 April 2026.

2

International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2009). https://database.ich.org/sites/default/files/Q8%28R2%29%20Guideline.pdf

ICH Q8(R2): Pharmaceutical development. Accessed Date: 22 April 2026.

3

International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2023). https://database.ich.org/sites/default/files/ICH_Q9%28R1%29_Guideline_Step4_2025_0115_0.pdf

ICH Q9(R1): Quality risk management. Accessed Date: 22 April 2026.

4

International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2008). https://database.ich.org/sites/default/files/Q10%20Guideline.pdf

ICH Q10: Pharmaceutical quality system. Accessed Date: 22 April 2026.

5

International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2012). https://database.ich.org/sites/default/files/Q11%20Guideline.pdf

ICH Q11: Development and manufacture of drug substances. Accessed Date: 22 April 2026.

6

International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2019). https://database.ich.org/sites/default/files/Q12_Guideline_Step4_2019_1119.pdf

ICH Q12: Technical and regulatory considerations for pharmaceutical product lifecycle management. Accessed Date: 22 April 2026.

7

U.S. Food and Drug Administration. (n.d.). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q8r2-pharmaceutical-development

ICH Q8(R2): Pharmaceutical development. Accessed Date: 22 April 2026.

8

U.S. Food and Drug Administration. (2004). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pat-framework-innovative-pharmaceutical-development-manufacturing-and-quality-assurance

PAT: A framework for innovative pharmaceutical development, manufacturing, and quality assurance. Accessed Date: 22 April 2026.

The opinions, information and conclusions contained within this blog should not be construed as conclusive fact, ValGenesis offering advice, nor as an indication of future results.

Related Blog Posts